GALWAY, Ireland - DexCom , Inc. (NASDAQ: DXCM), known for its real-time continuous glucose monitoring (rtCGM) systems, has commenced construction of its first European manufacturing facility in Athenry, Co. Galway. The new site is poised to generate over 1,000 jobs in the region, significantly impacting the local economy.
The facility will play a crucial role in distributing Dexcom (NASDAQ:DXCM)'s rtCGM sensors across Europe, the Middle East, and Africa (EMEA), with the potential to reduce costs and enhance sustainability by shortening delivery times. The site's strategic location is intended to bolster Dexcom's commitment to sustainable growth and operational excellence within the EMEA market.
Job opportunities at the new plant will span various fields, including finance, human resources, and engineering, with positions available from leadership to graduate levels. Dexcom aims to foster relationships with local universities, particularly in engineering and quality assurance disciplines, to support workforce development.
In addition to the economic benefits from direct employment, the investment is expected to create an additional 1 to 1.7 indirect jobs for each position at Dexcom, as per statistics from IDA. This multiplier effect underscores the broader impact of Dexcom's expansion on the local job market.
Dexcom's establishment in Ireland reflects the company's strategy to tap into the country's talent pool and provide meaningful work opportunities. The move aligns with Dexcom's mission to empower individuals in managing their health through innovative CGM technology.
Further cementing its commitment to the region, Dexcom has entered into a 12-year naming-rights partnership with Connacht Rugby, renaming 'The Sportsground' to 'Dexcom Stadium'. This partnership is indicative of Dexcom's long-term investment in the West of Ireland.
This information is based on a press release statement from DexCom, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.